Galera Therapeutics to Host Virtual KOL Event on the Treatment of Locally Advanced Pancreatic Cancer
September 22, 2020 08:00 ET
|
Galera Therapeutics
MALVERN, Pa., Sept. 22, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...
Galera Therapeutics Announces Dosing of First Patient in a Randomized, Double-Blind Pilot Phase 2 Clinical Trial of GC4419 for COVID-19
September 16, 2020 08:00 ET
|
Galera Therapeutics
Trial to enroll up to 50 hospitalized adults critically ill with COVID-19 Company continues to advance its three ongoing trials evaluating the potential of GC4419 to address radiation toxicities and...
Galera Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
September 14, 2020 08:00 ET
|
Galera Therapeutics
MALVERN, Pa., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...
Galera Therapeutics Announces ASTRO Late-Breaker Presentation of Topline Safety and Efficacy Data from its Double-Blind, Placebo-Controlled Phase 1b/2a Clinical Trial of GC4419 in Combination with SBRT for Locally Advanced Pancreatic Cancer
September 08, 2020 08:00 ET
|
Galera Therapeutics
MALVERN, Pa., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), is a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of...
Galera Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Updates
August 10, 2020 07:00 ET
|
Galera Therapeutics
Completed Enrollment of Randomized, Blinded, Placebo-controlled Trial of GC4419 in Combination with Radiotherapy in Locally Advanced Pancreatic Cancer; Topline Data Readout Expected in 2H20 Phase 3...
Galera Therapeutics to Participate in Fireside Chat at 2020 BTIG Virtual Biotechnology Conference
July 30, 2020 08:00 ET
|
Galera Therapeutics
MALVERN, Pa., July 30, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...
Galera Therapeutics Completes Enrollment of Phase 1b/2a Clinical Trial of GC4419 in Combination with Radiotherapy for Locally Advanced Pancreatic Cancer
July 13, 2020 17:46 ET
|
Galera Therapeutics
MALVERN, Pa., July 13, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...
Galera Therapeutics Announces Avasopasem Manganese Improved Markers of Chronic Kidney Disease in Patients Receiving Cisplatin
May 29, 2020 08:00 ET
|
Galera Therapeutics
MALVERN, Penn., May 29, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...
Galera Therapeutics to Host Virtual KOL Event on Cisplatin-Induced Chronic Kidney Disease
May 18, 2020 16:05 ET
|
Galera Therapeutics
MALVERN, Pa., May 18, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...
Galera Therapeutics Announces New Data from the Phase 2b Trial on the Effect of Avasopasem Manganese on Cisplatin-Induced Chronic Kidney Disease to be Presented at ASCO 2020 Virtual Scientific Program
May 13, 2020 17:19 ET
|
Galera Therapeutics
MALVERN, Pa., May 13, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...